Moleculin Biotech, UNC sign Annamycin research pact on 11/12/2025

Accepted by SEC EDGAR 11/12/2025 - 09:02 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) reported that it entered into a research and material transfer agreement with the University of North Carolina at Chapel Hill to support investigator‑initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer. The company furnished this update via an 8‑K, noting that the related press release is attached as Exhibit 99.1.

The disclosure is provided under a furnished information item and is not deemed filed. This agreement enables UNC investigators to conduct preclinical studies of Annamycin in pancreatic cancer models, reflecting continued nonclinical development activity around Moleculin’s anthracycline candidate.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moleculin Biotech (MBRX) announce?

Moleculin announced a research and material transfer agreement with UNC for investigator‑initiated preclinical research evaluating Annamycin in pancreatic cancer.

Which program is involved in the MBRX update?

The update involves Annamycin, Moleculin’s anthracycline candidate, to be studied in preclinical pancreatic cancer research.

What form did MBRX use to disclose this news?

The company furnished the information in a Form 8‑K, with a press release attached as Exhibit 99.1.

Who is Moleculin’s collaborator in this agreement?

The collaborator is the University of North Carolina at Chapel Hill (UNC).

When was the announcement made?

The company reported the agreement on November 12, 2025.

Is this research clinical or preclinical?

The filing describes the work as investigator‑initiated preclinical research.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001659617 0001659617 2025-11-12 2025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 12, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On November 12, 2025, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced it has entered into research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC) for investigator-initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer.

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Releasedated November 12, 2025
104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	November 12, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster